Resmed (RMD) closed at $239.53 on November 13, 2026, up 0.3% from the previous close, on volume of 787,363 shares (30-day average 1,279,735).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Ratio Put Spread 1 by 2.08 | 15-Jan-27210[2.08x] : 250 P | 1,540 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Wed, 11-Nov 5:27 AM ET)
PRNewswire (Mon, 9-Nov 9:11 PM ET)
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
Globe Newswire (Thu, 29-Oct 4:05 PM ET)
Resmed Launches AirTouch F40 Full Face Fabric CPAP Mask in the U.S.
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
Globe Newswire (Thu, 1-Oct 4:05 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
PRNewswire (Thu, 27-Aug 4:16 PM ET)
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
Globe Newswire (Thu, 27-Aug 4:05 PM ET)
Globe Newswire (Tue, 25-Aug 9:00 AM ET)
Globe Newswire (Mon, 17-Aug 4:10 PM ET)
ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
Resmed trades on the NYSE stock market under the symbol RMD.
As of November 13, 2026, RMD stock price climbed to $239.53 with 787,363 million shares trading.
RMD has a beta of 0.25, meaning it tends to be less sensitive to market movements. RMD has a correlation of 0.01 to the broad based SPY ETF.
RMD has a market cap of $33.69 billion. This is considered a Large Cap stock.
Last quarter Resmed reported $1 billion in Revenue and $2.91 earnings per share. This beat revenue expectation by $23 million and exceeded earnings estimates by $.24.
In the last 3 years, RMD traded as high as $293.81 and as low as $144.29.
The top ETF exchange traded funds that RMD belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
RMD has underperformed the market in the last year with a return of -4.0%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RMD shares. However, RMD has outperformed the market in the last 3 month and 2 week periods, returning +6.2% and +4.5%, while SPY returned -2.8% and -0.2%, respectively. This indicates RMD has been having a stronger performance recently.
RMD support price is $233.22 and resistance is $244.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RMD shares will trade within this expected range on the day.
